Tech Company Financing Transactions
Manifold Bio Funding Round
Manifold Bio secured a $40 million venture capital round on 7/14/2022. Backers included Triatomic Capital, FAST -- by GETTYLAB and Fifty Years.
Transaction Overview
Company Name
Announced On
7/14/2022
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Triatomic Capital (Lead Investor) (Jeff Huber)
Fifty Years (Seth Bannon)
Playground Global (Jory Bell)
Proceeds Purpose
The company intends to use the funds to advance its internal drug programs and expand its protein engineering platform to support additional programs and partnerships.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
127 Western Ave.
Allston, MA 02134
USA
Allston, MA 02134
USA
Phone
Undisclosed
Website
Email Address
Overview
Manifold Bio's mission is to build technology that exponentially increases measurement throughput at all stages of drug development. Increasing the number of drugs tested in these representative systems would provide data for learning design principles of drugs with optimal and unique properties in the most challenging disease environments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gleb Kuznetsov
Chief Scientific Officer
Pierce Ogden
Co-Founder
George Church
VP - Bus. Development
Shane Lofgren
Browse more venture capital transactions:
Prev: 7/14/2022: NutriSense venture capital transaction
Next: 7/14/2022: Here.co venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs